Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $207
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth maintains an Equal-Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $161 to $207.
June 25, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Tiago Fauth maintains an Equal-Weight rating on Alnylam Pharmaceuticals and raises the price target from $161 to $207.
The raised price target from $161 to $207 by a reputable analyst at Wells Fargo is a positive signal for investors, indicating potential upside. However, the Equal-Weight rating suggests a balanced view, which may temper the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100